Cargando…

IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation

BACKGROUND: Karyopherin nuclear transport receptors play important roles in tumour development and drug resistance and have been reported as potential biomarkers and therapeutic targets for tumour treatment. However, IPO5, one of the karyopherin nuclear transport receptor family members, remains lar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenjuan, Lu, Yanxia, Li, Xiaomin, Zhang, Jianming, Lin, Weihao, Zhang, Wei, Zheng, Lin, Li, Xuenong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617704/ https://www.ncbi.nlm.nih.gov/pubmed/31288861 http://dx.doi.org/10.1186/s13046-019-1290-0

Ejemplares similares

NIT1 suppresses tumour proliferation by activating the TGFβ1–Smad2/3 signalling pathway in colorectal cancer
por: Lin, Chun, et al.
Publicado: (2018)

The LncRNA CASC11 Promotes Colorectal Cancer Cell Proliferation and Migration by Adsorbing miR-646 and miR-381-3p to Upregulate Their Target RAB11FIP2
por: Zhang, Wei, et al.
Publicado: (2021)

IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway
por: Hong, Min, et al.
Publicado: (2018)

HMGB3 promotes growth and migration in colorectal cancer by regulating WNT/β-catenin pathway
por: Zhang, Zheying, et al.
Publicado: (2017)

Nuclear Transporter IPO13 Is Central to Efficient Neuronal Differentiation
por: Gajewska, Katarzyna A., et al.
Publicado: (2022)

IPO11 mediates βcatenin nuclear import in a subset of colorectal cancers
por: Mis, Monika, et al.
Publicado: (2019)

Soft fibrin gels promote selection and growth of tumourigenic cells
por: Liu, Jing, et al.
Publicado: (2012)

CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation
por: Lin, Zigen, et al.
Publicado: (2022)

Small GTPase RAB6 deficiency promotes alveolar progenitor cell renewal and attenuates PM2.5-induced lung injury and fibrosis
por: Yang, Lawei, et al.
Publicado: (2020)

High-profit IPO strategies: finding breakout IPOs for investors and traders
por: Taulli, Tom, et al.
Publicado: (2013)

circCDYL2, Overexpressed in Highly Migratory Colorectal Cancer Cells, Promotes Migration by Binding to Ezrin
por: Li, Xiaomin, et al.
Publicado: (2021)

Correction for: CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation
por: Lin, Zigen, et al.
Publicado: (2023)

NMDAR signaling facilitates the IPO5-mediated nuclear import of CPEB3
por: Chao, Hsu-Wen, et al.
Publicado: (2012)

microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity
por: Zhang, J, et al.
Publicado: (2010)

Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells
por: Ouyang, N, et al.
Publicado: (2010)

Corporate governance in IPO firms
por: Lehmann, Erik E, et al.
Publicado: (2020)

Overexpression of RASAL1 Indicates Poor Prognosis and Promotes Invasion of Ovarian Cancer
por: Chang, Rui-Xia, et al.
Publicado: (2019)

The tumourigenicity of iPS cells and their differentiated derivates
por: Liu, Zhiqiang, et al.
Publicado: (2013)

RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma
por: Yue, Yangyang, et al.
Publicado: (2022)

Hypermethylation of RASAL1: A Key for Renal Fibrosis
por: Mao, Yuanjie
Publicado: (2014)

RASAL2 Plays Inconsistent Roles in Different Cancers
por: Zhou, Bolun, et al.
Publicado: (2019)

Phosphorylated Rasal2 facilitates breast cancer progression
por: Wang, Xuan, et al.
Publicado: (2019)

IPO5 Mediates EMT and Promotes Esophageal Cancer Development through the RAS-ERK Pathway
por: Li, Meiyu, et al.
Publicado: (2022)

circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop
por: Li, Xiaomin, et al.
Publicado: (2022)

IPO7 promotes pancreatic cancer progression via regulating ERBB pathway
por: Li, Ming, et al.
Publicado: (2022)

RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis
por: Huang, Yuting, et al.
Publicado: (2014)

RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer
por: Pan, Yi, et al.
Publicado: (2018)

Latent class analysis of IPOs in the Nordics
por: Bask, Mikael, et al.
Publicado: (2021)

Mutation of IPO13 causes recessive ocular coloboma, microphthalmia, and cataract
por: Huang, Xiu-Feng, et al.
Publicado: (2018)

Mutagenic and tumourigenic properties of the spores of Aspergillus clavatus.
por: Blyth, W., et al.
Publicado: (1982)

Reduced tumourigenicity of EG7 after RANTES gene transfer and the underlying mechanism
por: Li, Jiuzhou, et al.
Publicado: (2010)

miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1
por: Chen, Hong, et al.
Publicado: (2018)

RASAL1 induces to downregulate the SCD1, leading to suppression of cell proliferation in colon cancer via LXRα/SREBP1c pathway
por: Wang, Guangchuan, et al.
Publicado: (2019)

The expression and function of RASAL2 in renal cell carcinoma angiogenesis
por: Hui, Ke, et al.
Publicado: (2018)

Rasal2, highlighting the importance of phosphorylation on function in tumour development
por: Galindo-Hernandez, Octavio
Publicado: (2020)

Competitive threat and strategic disclosure during the IPO quiet period
por: Qiu, Yetaotao, et al.
Publicado: (2022)

Correction: Latent class analysis of IPOs in the Nordics
Publicado: (2023)

MACC1 Down-Regulation Inhibits Proliferation and Tumourigenicity of Nasopharyngeal Carcinoma Cells through Akt/β-Catenin Signaling Pathway
por: Meng, Fengjiao, et al.
Publicado: (2013)

RPRM negatively regulates ATM levels through its nuclear translocation on irradiation mediated by CDK4/6 and IPO11
por: Zhang, Yarui, et al.
Publicado: (2022)

Suppressive effects of RASAL2 on renal cell carcinoma via SOX2/ERK/p38 MAPK pathway
por: Wang, Sen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t22r02bp2j984r16thd9h09k29